Skip to content

Study · Non-randomized trial · 2012

9 results

Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study.

Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Oostdijk W and 12 more

Show all authors

Bocca G, Mieke Houdijk EC, van Trotsenburg AS, Hoorweg-Nijman JJ, van Wieringen H, Vreuls RC, Jira PE, Schroor EJ, van Pinxteren-Nagler E, Willem Pilon J, Lunshof LB, Hokken-Koelega AC

The Journal of clinical endocrinology and metabolism16 Apr 2012Cited by 105 (Europe PMC)

PMID22508707 (opens in a new tab)DOI10.1210/jc.2012-1182 (opens in a new tab)PepBankPUB-22508707
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal children with Prader-Willi syndrome, mean cognitive subtest scores stayed similar to baseline over 2 years with growth hormone, whereas they decreased in untreated controls.

    In plain wordsIn children with Prader-Willi syndrome, cognitive subtest scores stayed similar to baseline with growth hormone but fell in untreated controls.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeCognitive subtest scores during randomized trial
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    During the randomized controlled trial, mean sd scores of all subtests and mean TIQ score remained similar compared to baseline in GH-treated children with PWS, whereas in untreated controls mean subtest sd scores and mean TIQ score decreased and became lower compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In prepubertal children with Prader-Willi syndrome, mean total IQ stayed similar to baseline over 2 years with growth hormone, whereas it decreased in untreated controls.

    In plain wordsIn children with Prader-Willi syndrome, total IQ stayed similar to baseline with growth hormone but fell in untreated controls.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeTotal IQ during randomized trial
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    During the randomized controlled trial, mean sd scores of all subtests and mean TIQ score remained similar compared to baseline in GH-treated children with PWS, whereas in untreated controls mean subtest sd scores and mean TIQ score decreased and became lower compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with Prader-Willi syndrome, Similarities scores increased after growth hormone treatment versus baseline (P = 0.01).

    In plain wordsIn children with Prader-Willi syndrome, Similarities scores increased after growth hormone treatment versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseSimilarities subtest score
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After 4 yr of GH treatment, mean sd scores on the Similarities and Block design subtests were significantly higher than at baseline (P = 0.01 and P = 0.03, respectively), and scores on Vocabulary and TIQ remained similar compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with Prader-Willi syndrome, Block design scores increased after growth hormone treatment versus baseline (P = 0.03).

    In plain wordsIn children with Prader-Willi syndrome, Block design scores increased after growth hormone treatment versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBlock design subtest score
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After 4 yr of GH treatment, mean sd scores on the Similarities and Block design subtests were significantly higher than at baseline (P = 0.01 and P = 0.03, respectively), and scores on Vocabulary and TIQ remained similar compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with Prader-Willi syndrome, Vocabulary scores remained similar to baseline after growth hormone treatment.

    In plain wordsIn children with Prader-Willi syndrome, Vocabulary scores remained similar to baseline after growth hormone treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeVocabulary subtest score
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After 4 yr of GH treatment, mean sd scores on the Similarities and Block design subtests were significantly higher than at baseline (P = 0.01 and P = 0.03, respectively), and scores on Vocabulary and TIQ remained similar compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with Prader-Willi syndrome, total IQ remained similar to baseline after growth hormone treatment.

    In plain wordsIn children with Prader-Willi syndrome, total IQ remained similar to baseline after growth hormone treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeTotal IQ after longitudinal treatment
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    After 4 yr of GH treatment, mean sd scores on the Similarities and Block design subtests were significantly higher than at baseline (P = 0.01 and P = 0.03, respectively), and scores on Vocabulary and TIQ remained similar compared to baseline.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  7. 07HumanObservational studyEfficacy outcome

    During growth hormone treatment, children with Prader-Willi syndrome and maternal uniparental disomy had larger Block design increments than children with a deletion.

    In plain wordsDuring growth hormone treatment, children with Prader-Willi syndrome and maternal uniparental disomy had larger Block design increments than children with a deletion.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBlock design increment by genetic subgroup
    Study

    n: not reported in source

    Comparator
    Children with a deletion
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    At baseline, children with a maternal uniparental disomy had a significantly lower score on the Block design subtest (P = 0.01) but a larger increment on this subtest during 4 yr of GH treatment than children with a deletion.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  8. 08HumanObservational studyEfficacy outcome

    In children with Prader-Willi syndrome receiving growth hormone, lower baseline scores correlated with larger Similarities score increases (P = 0.04).

    In plain wordsIn children with Prader-Willi syndrome receiving growth hormone, lower baseline scores were linked to larger Similarities score increases.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableBaseline score association with Similarities increase
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    Lower baseline scores correlated significantly with higher increases in Similarities (P = 0.04) and Block design (P < 0.0001) sd scores.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.
  9. 09HumanObservational studyEfficacy outcome

    In children with Prader-Willi syndrome receiving growth hormone, lower baseline scores correlated with larger Block design score increases (P < 0.0001).

    In plain wordsIn children with Prader-Willi syndrome receiving growth hormone, lower baseline scores were linked to larger Block design score increases.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableBaseline score association with Block design increase
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    Lower baseline scores correlated significantly with higher increases in Similarities (P = 0.04) and Block design (P < 0.0001) sd scores.
    1 context sentence
    Summary · context
    Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.